CONCORD, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its ...
CUPERTINO, Calif., Oct. 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the results from the recently completed Phase 2a study of DUR-928 in patients with alcoholic ...
ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be presented as a poster at the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback